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Abstract
We describe a family with a history of breast and ovarian cancer in which MLPA analysis of the BRCA1 gene pointed
to a deletion including a part of exon 11. Further characterization confirmed a loss of 374 bp in a region completely
covered by conventional sequencing which had not revealed the deletion. Because this alteration was only detected
serendipitously with an MLPA probe, we calculated the probabilities of detecting medium-sized deletions in large
exons by methods including initial PCR amplification. This showed that a considerable fraction of medium-sized de-
letions are undetectable by currently used standard methods of mutation analyses. We conclude that long, widely
overlapping amplicons should be used to minimize the risk of missing medium-sized deletions. Alternatively, large
exons could be completely covered by narrow-spaced MLPA probes.
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Numerous different mutations in the BRCA1 and
BRCA2 genes (Miki et al., 1994; Wooster et al., 1995)
have been identified in families with a history of breast and
ovarian cancer (King et al., 2003). Because of their broad
distribution, at least all exons and adjacent sequences have
to be covered by genetic testing. To identify substitutions
and small insertions or deletions, PCR amplification fol-
lowed by sequencing is still considered the diagnostic gold
standard.Inaddition,MLPA(multiplexligation-dependent
probe amplification) analyses (Hogervorst et al., 2003) can
reveallargedeletionsandrearrangementsnotdetectableby
sequencing. To reduce the time required for testing, pre-
screening methods like denaturing gradient chromatogra-
phy (Arnold et al., 2002) or analyses of melting curves of
PCR products (van der Stoep et al., 2009) are used. These
techniques, however, are still based on PCR-amplified
DNA and, compared to sequencing, their sensitivities are
lower. As a consequence of PCR amplification as a first
step in these sorts of analyses, medium-sized heterozygous
deletions affecting the binding site of one PCR primer are
not recognized. Although most molecular geneticists are
aware of this problem, calculations of the number of poten-
tially missed deletions have not been published.
Here we describe a 374 bp deletion not detected in a
large exon by sequencing that has been found only because
the deleted region was, by chance, covered by an MLPA
probe. By model calculations, we determined the likeli-
hood to find such medium-sized deletions and suggested
measures to increase it.
Clinicogenetic counselling was performed at the Fa-
milial Breast and Ovarian Cancer Center in Ulm. Genetic
testing including the BRCA1 and BRCA2 genes was de-
pendentontheriskcategoryassignedtothefamily.Inaddi-
tion,individualriskswerecalculatedwithCyrillic2.1pedi-
gree analyses software (Cyrillic Software, Wallingford,
UK).
Genomic DNA was isolated from blood with a Blood
& Cell Culture DNA Maxi Kit (Qiagen, Hilden, Gemany)
and all exons and adjacent regions of the BRCA1 and
BRCA2 genes were amplified by standard PCR with Fast
Start Taq Polymerase (Roche Diagnostics, Mannheim,
Germany). End of intron 10 and beginning of exon 11 was
covered by primers E11-F1 (5’-GATTTCCACCTCCAAG
GTGTATGA-3’) and E11-R1 (5’-GGGAGTCCGCCTAT
CATTACAT-3’).SequencingofthepurifiedPCRproducts
from both directions was performed according to the sup-
pliers’ instructions with the Dye Terminator Cycle Se-
quencing Kit (Beckman Coulter, Krefeld, Germany). The
generated fragments were purified (Agencourt CleanSEQ,
Beckman Coulter) and analysed by means of a CEQ 8000
sequencer (Beckman Coulter). Sequences were compared
to the BRCA1 reference cDNA sequence (NM_007294)
usingMutationSurveyorsoftware(Softgenetics,StateCol-
lege,PA,USA).Todescribemutations,positionsarecalcu-
lated from the translation initiation codon ATG (A = 1).
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Short CommunicationMLPAanalysisoftheBRCA1genewasdoneaccord-
ing to the protocol supplied by the manufacturer of the
SALSA-MLPA Kit P002 (MRC-Holland, Amsterdam,
Netherlands) and the products were analysed with the CEQ
8000 Gene Analysis System (Beckman Coulter).
The Long-Range PCR Kit from Qiagen was used for
PCR amplification with 100 ng of genomic template DNA
inatotalreactionvolumeof50Lunderthefollowingcon-
ditions: 3 min at 93 °C followed by 35 cycles of 15 s at
93 °C, 30 s at 58 °C and 4 min at 69 °C. Products were ana-
lysed by standard gel electrophoresis in 1% agarose gels.
Forward primer E10-F1 (5’-TAAGATTGGTCAGCTTT
CTGTAATC-3’, end of intron 9) was used in combination
with exon 11 reverse primers E11-R1, E11-R4 (5’-TCTA
TTGGGTTAGGATTTTTCTCA-3’), E11-R7 (5’-TTTTG
CCTTCCCTAGAGTGCTAAC-3’), E11-R11 (5’-AGAT
GCATGACTACTTCCCATAGG-3’), or E11-R13 (5’-
TATTTGCAGTCAAGTCTTCCAA-3’).
Genetic counselling and subsequent analyses of pre-
disposing genes was requested by a 53 years old woman on
the basis of her sister’s early-onset breast cancer and other
cases of breast and ovarian cancer in her family (Figu-
re 1A). Accordingly, her risk of developing breast cancer
was calculated to be 31%. By sequencing of all exons and
adjacent regions of the BRCA1 and BRCA2 genes, no
pathogenic mutation was detected. Subsequent MLPA
analyses showed a substantially reduced signal resulting
from only one of two MLPA probes binding to BRCA1
exon 11, suggesting a deletion including a region close to
the beginning of this exon. Long PCR with primers from
the end of exon 10 to various positions of exon 11 con-
firmed a heterozygous medium-sized deletion (Figure 1B).
These PCR products were subjected to sequence analysis
which showed a deletion (del c.671-26_1018) of 374 bp.
This deletion affected the binding site of one of the primers
used to amplify the DNA prior to sequencing for which, as
a consequence, only PCR products from the normal allele
were obtained. This case raised the question as to the
likelinessofdetectingsuchmedium-sizeddeletionsbyrou-
tine methodology.
Currentlyusedstrategiestodetectmutationsarejusti-
fied by two facts: (a) Substitutions and very small inser-
tions and deletions are most likely detected in PCR-ampli-
fied DNA by sequencing or pre-screening methods, and (b)
most of the large deletions are found by MLPA. As from
the case described herein we learned that a considerable
fraction of medium-sized deletions might not be detected
by conventional approaches, we performed model calcula-
tions to estimate the potential relevance of this problem.
The simplified model exon of length l was divided into a
number (q) of equally spaced PCR amplicons with a con-
stantoverlapoflengtha.Allprimerswereassumedtobeof
the same length p and all possible deletions of length d to
occur with the same likelihood over the entire region.
Short deletions, i.e. from single nucleotides to a size
smaller than the region between primers in the overlap of
amplicons (1 < d << a -2 p), can only lead to suppression of
the mutated allele if one of the terminal primers is affected,
because such variation of the binding site of an internal
primer is visible in the sequence from the overlapping PCR
product. If such a small deletion occurs within the analysed
region, the probability that the critical terminal primers are
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Figure1-Detectionofamedium-sizeddeletionintheBRCA1gene.A:FamilywithahistoryofbreastandovariancancerinwhichadeletioninBRCA1
wasfound.Twosistersofawomanwhohaddevelopedbreastcanceratage30harbouredthismutation(M),indicatedaremanifestationsofbreastcancer
(BC), ovarian cancer (OC) and colon cancer (CC). B: Characterization of the 374 bp deletion in exon 11 by long PCR. Amplified genomic regions in-
cludedexon10(E10)andthefollowingintronandpartsofexon11(E11),asshowninthetopscheme.Thedeletioninonealleleresultedindoublebands
of longer PCR products but not of the smallest one, which was generated with the reverse primer also used in routine sequencing. The amplicon used for
sequence analysis is shown in the scheme above the products of long PCR (A-E). Marker fragments labelled with an asterisk are 1500 bp, 3000 bp and
6000 bp.affectedisapproximately2*(d+p)/Lwhichisverylowfor
long exons. In addition, the terminal primers are usually lo-
cated in intronic sequences and small deletions in these re-
gions are rarely of any clinical relevance.
Incontrasttothereliablydetectedsmalldeletions,de-
letions longer than the PCR amplicons are never detected
by sequencing because they cannot be amplified. Deletions
of this size, affecting only part of a large exon, may not be
detectable at all through MLPA when wide-spaced MLPA
probes are used.
Most critical appear to be medium-sized deletions
which can be detected by chance only when using wide-
spacedMLPAprobes.Sequencingfailstodetectsuchdele-
tionsifbindingofaterminalprimerorbothprimersofadja-
cent amplicons in the overlapping region are affected.
Therefore,deletionssmallerthananampliconbutatleastof
the size of the region between primers in the overlap of
amplicons are not detected with high sensitivity.
For an exon of length l that is divided into q
ampliconswithoverlappingregionsofa,definedbyprimer
of constant lengths p, the likelihood P of missing a deletion
ofthesized(l/q>d>a-2p)whichoccursatarandomsitein
the analysed region can be calculated as:
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Figure 2A shows the function P(d) for parameters
typical for the analysis of BRCA1 exon 11. Obviously, a
substantial fraction of possible medium-sized deletions are
not detectable by sequencing, but the chance of their detec-
tion can be increased by reducing the number of PCR
amplicons and by expanding the overlapping regions (Fig-
ure 2).
Initiated by the MLPA-based detection of deletion
thatwasmisseddespitesequenceanalysiscoveringtheaf-
fected region, we performed model calculations to esti-
mate the fractions of medium-sized deletions that cannot
be discovered by conventional methods. These were sur-
prisingly high under typical conditions, especially for de-
letionsizesjustbelowtheampliconlengths.Thecurrently
usedBRCA1MLPAkitscontainonlytwoprobesforexon
11, and therefore only few of such medium-sized dele-
tions can be found using this approach. We conclude that
compared to small and large deletions, which are reliably
found using conventional sequencing and MLPA, the sen-
sitivity of detection of medium-sized deletions with these
methods is very low. To increase sensitivity, a set of nar-
row-spaced MLPA probes could be used. Alternatively,
amplification of complete large exons by long PCR fol-
lowed by high resolution gel electrophoresis should re-
solve the problem.
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Figure2-Probabilityofmissingmedium-sizeddeletionsinlongexonsbysequencingofoverlappingPCRproductsdependsonthenumberofamplicons
and the size of the overlapping regions. Based on a simplified model of deletions occurring with the same likelihood over the analysed region, and analy-
sis with primers of constant (25 nt) lengths resulting in q amplicons of the same extent, calculations (see Results section) were performed for a regiono f
the size of BRCA exon 11 (3426 bp). A: Sequence analysis based on 10 PCR amplicons overlapping 100 bp or 200 bp. B: Sequence analysis based on 5
PCR amplicons overlapping 100 bp or 200.References
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